Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer

BACKGROUND: Although immune checkpoint inhibitors (ICI) targeting for PD-1 axis is a promising approach for advanced gastric cancer (GC) patients, the response rate is still limited. Induction of synergistic effect of irradiation with ICI targeting for the PD-1 axis can be an attractive strategy. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Kosaku, Ogata, Takashi, Yoshimoto, Yuya, Yoshida, Daisaku, Nakajima, Shotaro, Sato, Hisashi, Machida, Nozomu, Yamada, Takanobu, Watanabe, Yohei, Tamaki, Tomoaki, Fujikawa, Hirohito, Inokuchi, Yasuhiro, Hayase, Suguru, Hanayama, Hiroyuki, Saze, Zenichiro, Katoh, Hiroyuki, Takahashi, Fumiaki, Oshima, Takashi, Suzuki, Yoshiyuki, Kono, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427681/
https://www.ncbi.nlm.nih.gov/pubmed/37582945
http://dx.doi.org/10.1038/s43856-023-00343-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427681/
https://www.ncbi.nlm.nih.gov/pubmed/37582945
http://dx.doi.org/10.1038/s43856-023-00343-4

Ejemplares similares